Tue, April 19, 2022
Mon, April 18, 2022
Sun, April 17, 2022
Thu, April 14, 2022
Wed, April 13, 2022
Tue, April 12, 2022
Mon, April 11, 2022

Raghuram Selvaraju Maintained (BTAI) at Strong Buy with Increased Target to $134 on, Apr 14th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-increased-target-to-134-on-apr-14th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Raghuram Selvaraju of HC Wainwright & Co., Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $130 to $134 on, Apr 14th, 2022.

Raghuram has made no other calls on BTAI in the last 4 months.



There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.



This is the rating of the analyst that currently disagrees with Raghuram


  • Colin Bristow of "UBS" Maintained at Strong Buy with Decreased Target to $25 on, Wednesday, February 16th, 2022

Publication Contributing Sources